Healthcare Services US

US Alzheimer's Diagnostics Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

US Alzheimer’s Diagnostic Market Industry Trends and Forecast to 2034: Segmented by (Type, Diagnostic Test, End Users) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

US · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $925.2 Mn Placeholder estimate
Estimate 2025 $970.6 Mn 40.4% of the global market
Projected 2034 $1.49 Bn 53.8% Adds $522.2 Mn over 9 forecast years
CAGR 2025–2034 4.9% Faster than 22% of 107 Healthcare Services markets here
Key players 19 +14
  • US is 40.44% of the global market.
  • In North America, the largest is US (this report) at $970.6 Mn.
  • Fastest growing: Canada at 6.9% a year.
  • US ranks 1st of 2 by size in North America.

Market size projection

US

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$522.2 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Alzheimer's Diagnostics Market market size by year, US
YearMarket sizeChange that yearSince 2025
2024 (estimate) $925.2 Mn — —
2025 (base) $970.6 Mn +$45.3 Mn —
2026 (forecast) $1.02 Bn +$47.6 Mn +4.9%
2027 (forecast) $1.07 Bn +$49.9 Mn +10%
2028 (forecast) $1.12 Bn +$52.3 Mn +15.4%
2029 (forecast) $1.18 Bn +$54.9 Mn +21.1%
2030 (forecast) $1.23 Bn +$57.6 Mn +27%
2031 (forecast) $1.29 Bn +$60.4 Mn +33.2%
2032 (forecast) $1.36 Bn +$63.4 Mn +39.8%
2033 (forecast) $1.42 Bn +$66.5 Mn +46.6%
2034 (forecast) $1.49 Bn +$69.7 Mn +53.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

US Alzheimer's Diagnostics Market Analysis at a glance
Market size, 2025$970.6 Mn placeholder estimate
Forecast, 2034$1.49 Bn placeholder estimate
Growth (CAGR), 2025–20344.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
Also calledAlzheimer's Disease Diagnostics
SegmentsType (see all)
Key playersAbbVie Inc., AC Immune (Switzerland), AMARANTUS BIOSCIENCE HOLDINGS, INC., Anavex Life Sciences Corp., Eli Lilly and Company and 14 more (see all)
Active clinical trials429 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 9 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The US Alzheimer’s Diagnostic Market Analysis Executive Summary

Alzheimer's disease is a degenerative brain illness that worsens with time. Changes in the brain that result in the deposition of specific proteins are its defining feature. The brain shrinks and brain cells finally die as a result of Alzheimer's disease. The most frequent cause of dementia—a progressive loss of thinking, memory, conduct, and social skills—is Alzheimer's disease. A person's capacity to function is impacted by these changes. Forgetting previous discussions or occurrences is one of the disease's early symptoms. It worsens with time, leading to severe memory loss and diminished capacity for daily activities. Among older adults worldwide, dementia is one of the main causes of dependency and disability and currently ranks as the sixth most common cause of mortality.

At present, about 55 million individuals globally suffer with dementia, with more than 60% residing in low- and middle-income nations. There are around 10 million new cases annually. A wide range of brain traumas and illnesses can cause dementia. As the most prevalent type of dementia, Alzheimer's disease may be a factor in 60–70% of cases. In the US, 6.5 million adults 65 years of age and older have Alzheimer's disease. Over 70% of them are 75 years of age or older. 60% to 70% of the approximately 55 million persons with dementia globally are thought to have Alzheimer's disease.

Bar chart: US Alzheimer's Diagnostics market size, 2024–2034, placeholder estimates. $925.2 Mn in 2024, $970.6 Mn in 2025 and $1.49 Bn in 2034, 4.9% CAGR.
US Alzheimer's Diagnostics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Market Dynamics for Alzheimer’s Diagnostic Market in the US

Market Growth Drivers Analysis

A key factor propelling the US Alzheimer’s diagnostic market is the increasing incidence of Alzheimer's disease throughout the world. There is a rising need for diagnostic tools and tests as the aging population grows and more people become afflicted with Alzheimer's disease. This has thus cleared the path for the market's expansion.

The significance of early identification and treatment for Alzheimer's disease is becoming more widely recognized. US Alzheimer’s diagnostic market demand is driven by the benefits of early detection, such as improved symptom management, access to support services, and potential involvement in clinical trials.

Advances in imaging modalities, genetic testing strategies, and biomarkers have increased the precision and dependability of diagnosing Alzheimer's disease. The use of diagnostic instruments and tests in clinical practice is fueled by these developments.

Opportunity

Raising Per Capita Expenditure

Growth opportunities for market players are provided by government programs, schemes, or funding that support and encourage research and development in the US Alzheimer’s diagnostic market growth.during the projected period of 2025 to 2030. The US Alzheimer’s diagnostic market growth rate will also be further accelerated in the future by creating biomarkers, penetration rates, market expansion in developing nations, integration of numerous diagnostic methods globally, and rising per capita health care spending.

Market Restraints

Despite there are drugs that help lessen symptoms for a while, Alzheimer's disease cannot be cured. The absence of conclusive treatment options could limit the market's expansion and have an effect on its potential for US Alzheimer’s diagnostic market growth.

Alzheimer's disease has a complex pathology involving multiple factors and mechanisms. Understanding the disease progression and identifying reliable biomarkers that accurately reflect the disease state remains a challenge.

The lack of suitable infrastructure and unfavorable reimbursement scenario in low- and middle-income countries are projected to challenge the US Alzheimer’s diagnostic market growth.

Competitive Landscape for Alzheimer’s Diagnostic Market in the US

Key Players

Recent Developments

In May 4, 2022, , Fujirebio, a division of H.U. Group Holdings, Inc., a manufacturer and supplier of in vitro diagnostics products, declared that the FDA had approved its Lumipulse G β-Amyloid Ratio (1-42/1-40) in vitro diagnostic test for use in diagnosing Alzheimer's disease in the US.

In 2022, In order to determine the density and location of aggregated tau neurofibrillary tangles in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease, the US FDA approved Eli Lilly's TAUVIDTM, a radioactive diagnostic agent for PET imaging of the brain.

Mergers and Acquisitions

In June 2021, the Alzheimer's Drug Discovery Foundation (ADDF) Diagnostics Accelerator released four new research investments to develop digital biomarkers for Alzheimer's disease diagnosis.

In March 1, 2022, Quanterix, a life sciences company and Eli Lilly and Company, a pharmaceutical company announced that they have signed a collaboration agreement for the diagnosis, monitoring, and treatment of Alzheimer's disease

Healthcare Policies and Regulatory Landscape for Alzheimer’s Diagnostic Market in the US

Alzheimer's Diagnostics in the US: payment and research

Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).⁠[1] ClinicalTrials.gov lists 429 studies on Alzheimer's Diagnostics that are recruiting, active or about to start in the US.⁠[2]

[1] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

[2] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 9 Nov 2026.

Policy changes and Reimbursement scenario

Governments and non-government organizations are investing heavily in the research and development of diagnostics and therapies for Alzheimer's disease, which may contribute to the market's expansion. Higher accessibility and affordability of Alzheimer's disease diagnostic tools are anticipated to be observed in the market as more companies enter it and competition intensifies.

Regulatory bodies are anticipated to expedite approval procedures as biomarkers become increasingly confirmed and standardized, ensuring that safe and efficient diagnostic instruments quickly hit the market. More accessibility and affordability of Alzheimer's disease diagnostic tools are expected to be seen in the market as more businesses enter the industry and competition heats up.

The market for Alzheimer's disease diagnostics is also expected to be significantly impacted by regulatory bodies that collaborate with industry players to foster an environment that is conducive to innovation. Even while new diagnostics are getting regulatory approvals more frequently, there are still a lot of obstacles to overcome, particularly in low- and middle-income nations, including high costs and a lack of reimbursement. Nonetheless, in the upcoming years, it is anticipated that policy modifications intended to hasten approvals, boost investments, and promote competition will enhance the regulatory environment and accessibility of Alzheimer's diagnostics.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Alzheimer's Diagnostics right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 9 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Alzheimer's Diagnostics in context

The US compared

  • Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
  • Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
  • People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 20 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.

Free data on this topic

Inside the US

Quick answers

Frequently asked questions

How big is the Alzheimer's Diagnostics market in the US?
Placeholder estimate: about $970.6 Mn in 2025, rising to about $1.49 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Alzheimer's Diagnostics market in the US growing?
Placeholder estimate: about 4.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Alzheimer's Diagnostics market report cover?
The report splits the market by type (Nervous System, Examination, Genetic Testing, Minor Mental State Examination and more).
Who are the key players in the Alzheimer's Diagnostics market?
Key players include AbbVie Inc., AC Immune (Switzerland), AMARANTUS BIOSCIENCE HOLDINGS, INC., Anavex Life Sciences Corp., Eli Lilly and Company and AXON Neuroscience (Slovakia), among 19 companies the report profiles.
What is driving the Alzheimer's Diagnostics market?
A key factor propelling the US Alzheimer’s diagnostic market is the increasing incidence of Alzheimer's disease throughout the world. There is a rising need for diagnostic tools and tests as the aging population grows and more people become afflicted with Alzheimer's disease.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Alzheimer's Diagnostics are running in the US?
429 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 9 Nov 2026.
How much research is published on Alzheimer's Diagnostics?
PubMed lists 32,074 papers on Alzheimer's Diagnostics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 9 Nov 2026.
Back to Catalogue

Related Healthcare Services reports in US

See all

Related on alzheimer's and diagnostics and lab testing

See the topic